However, when we look into liver cancer, the p53 cell cycle signalling pathway is altered in at least 50% of patients with hepatocellular carcinoma (HCC), a disease often associated with p53 mutations, occurring in 12% to 48% of cases6. The gene discussed is TP53; the disease is liver cancer.